Literature DB >> 18707827

Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.

Daniel R Gomez1, Joanne E Zhung, Jennifer Gomez, Kelvin Chan, Abraham J Wu, Suzanne L Wolden, David G Pfister, Ashok Shaha, Jatin P Shah, Dennis H Kraus, Richard J Wong, Nancy Y Lee.   

Abstract

PURPOSE: To present our single-institution experience of intensity-modulated radiotherapy (IMRT) for oral cavity cancer. METHODS AND MATERIALS: Between September 2000 and December 2006, 35 patients with histologically confirmed squamous cell carcinoma of the oral cavity underwent surgery followed by postoperative IMRT. The sites included were buccal mucosa in 8, oral tongue in 11, floor of the mouth in 9, gingiva in 4, hard palate in 2, and retromolar trigone in 1. Most patients had Stage III-IV disease (80%). Ten patients (29%) also received concurrent postoperative chemotherapy with IMRT. The median prescribed radiation dose was 60 Gy.
RESULTS: The median follow-up for surviving patients was 28.1 months (range, 11.9-85.1). Treatment failure occurred in 11 cases as follows: local in 4, regional in 2, and distant metastases in 5. Of the 5 patients with distant metastases, 2 presented with dermal metastases. The 2- and 3-year estimates of locoregional progression-free survival, distant metastasis-free survival, disease-free survival, and overall survival were 84% and 77%, 85% and 85%, 70% and 64%, and 74% and 74%, respectively. Acute Grade 2 or greater dermatitis, mucositis, and esophageal reactions were experienced by 54%, 66%, and 40% of the patients, respectively. Documented late complications included trismus (17%) and osteoradionecrosis (5%).
CONCLUSION: IMRT as an adjuvant treatment after surgical resection for oral cavity tumors is feasible and effective, with promising results and acceptable toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18707827     DOI: 10.1016/j.ijrobp.2008.05.024

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  34 in total

1.  A novel correction factor based on extended volume to complement the conformity index.

Authors:  F Jin; Y Wang; Y-Z Wu
Journal:  Br J Radiol       Date:  2011-11-29       Impact factor: 3.039

2.  Locoregional recurrences after post-operative volumetric modulated arc radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting: experience and lessons learned.

Authors:  S Chakraborty; V M Patil; S Babu; G Muttath; S K Thiagarajan
Journal:  Br J Radiol       Date:  2015-02-03       Impact factor: 3.039

3.  Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers.

Authors:  Benjamin H Lok; Christine Chin; Nadeem Riaz; Felix Ho; Man Hu; Julian C Hong; Weiji Shi; Zhigang Zhang; Eric Sherman; Richard J Wong; Luc G Morris; Ian Ganly; Suzanne L Wolden; Shyam S Rao; Nancy Y Lee
Journal:  Head Neck       Date:  2014-08-28       Impact factor: 3.147

4.  Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis.

Authors:  Michael T Spiotto; Gina Jefferson; Barry Wenig; Michael Markiewicz; Ralph R Weichselbaum; Matthew Koshy
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-07-01       Impact factor: 6.223

5.  Squamous cell carcinoma of the tonsil managed by conventional surgery and postoperative radiation.

Authors:  Rahmatullah Rahmati; Snjezana Dogan; Owen Pyke; Frank Palmer; Mahmoud Awad; Nancy Lee; Dennis H Kraus; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Head Neck       Date:  2014-06-19       Impact factor: 3.147

6.  Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.

Authors:  Gunjan Srivastava; Ajay Matta; Guodong Fu; Raj Thani Somasundaram; Alessandro Datti; Paul G Walfish; Ranju Ralhan
Journal:  Mol Oncol       Date:  2015-05-21       Impact factor: 6.603

7.  Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy.

Authors:  Sean R Quinlan-Davidson; Abdallah S R Mohamed; Jeffrey N Myers; Gary B Gunn; Faye M Johnson; Heath Skinner; Beth M Beadle; Ann M Gillenwater; Jack Phan; Steven J Frank; William N William; Andrew J Wong; Stephen Y Lai; Clifton D Fuller; William H Morrison; David I Rosenthal; Adam S Garden
Journal:  Oral Oncol       Date:  2017-07-16       Impact factor: 5.337

8.  Clinical outcomes for T1-2N0-1 oral tongue cancer patients underwent surgery with and without postoperative radiotherapy.

Authors:  Su Jung Shim; Jihye Cha; Woong Sub Koom; Gwi Eon Kim; Chang Geol Lee; Eun Chang Choi; Ki Chang Keum
Journal:  Radiat Oncol       Date:  2010-05-27       Impact factor: 3.481

9.  Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma.

Authors:  Pinaki R Dutta; Nadeem Riaz; Sean McBride; Luc G Morris; Snehal Patel; Ian Ganly; Richard J Wong; Frank Palmer; Heiko Schöder; Nancy Lee
Journal:  Head Neck       Date:  2015-09-03       Impact factor: 3.147

10.  Objective assessment of trismus in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT).

Authors:  Adepitan A Owosho; Luciana M Pedreira Ramalho; Haley I Rosenberg; SaeHee K Yom; Esther Drill; Elyn Riedel; C Jillian Tsai; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo
Journal:  J Craniomaxillofac Surg       Date:  2016-06-16       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.